Fig 1.
Flow chart showing enrollment of 81 patients.
MPGN, membranoproliferative glomerulonephritis; J-RBR, Japan Renal Biopsy Registry.
Table 1.
Clinicopathological findings at baseline and initial treatment between IC-MPGN and C3GN.
Table 2.
Clinical findings and outcomes after treatment between IC-MPGN and C3GN.
Fig 2.
Renal outcomes of IC-MPGN and C3GN.
Significant differences were observed in serum creatinine elevations of 50% (sCr × 1.5, A) and end-stage kidney disease (ESKD) (B) between IC-MPGN and C3GN patients. Kaplan-Meier curves for treated and untreated patients analyzed using log-rank tests. IC-MPGN, immune-complex membranoproliferative glomerulonephritis; C3GN, C3 glomerulonephritis.
Fig 3.
Renal outcomes of IC-MPGN patients with or without steroid pulse therapy stratified by median age (62 y) at onset in serum creatinine elevations of 50% (sCr × 1.5, A) and end-stage kidney disease (B).
Kaplan-Meier curves for treated and untreated patients analyzed using log-rank tests. IC-MPGN, immune-complex membranoproliferative glomerulonephritis; SP, steroid pulse.
Table 3.
Clinicopathological findings at baseline in patients with IC-MPGN stratified by median age (62 y) and with or without steroid pulse therapy at initial treatment.
Table 4.
Outcomes in patients with IC-MPGN stratified by median age (62 y) and with or without steroid pulse therapy at initial treatment.
Table 5.
Association of Serum creatinine×1.5 and progression to end-stage kidney disease in patients with IC-MPGN.